PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma

International Journal of Cancer

Volumn 129, Issue 1, 2011, Pages 34-44

  Loilome, Watcharin ^a,b   Juntana, Sirinun ^a,b   Namwat, Nisana ^a,b   Bhudhisawasdi, Vajarabhongsa ^a,b   Puapairoj, Anucha ^a,b   Sripa, Banchob ^a,b   Miwa, Masanao ^c   Saya, Hideyuki ^d   Riggins, Gregory J ^e   Yongvanit, Puangrat ^a,b  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^d KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cAMP dependent protein kinase; cholangiocarcinoma; protein kinase A regulatory subunit 1 alpha

Indexed keywords

BETA CATENIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IALPHA; CYCLIC AMP DEPENDENT PROTEIN KINASE REGULATORY SUBUNIT IIALPHA; JANUS KINASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT PROTEIN; WNT PROTEIN;

ADULT; APOPTOSIS; ARTICLE; BILE DUCT CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; AGED; APOPTOSIS; BILE DUCT NEOPLASMS; CELL PROLIFERATION; CHOLANGIOCARCINOMA; CYCLIC AMP-DEPENDENT PROTEIN KINASE RIALPHA SUBUNIT; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 79955377885     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25646     Document Type: Article

References (37)

1. Vatanasapt V, Sriamporn S, Vatanasapt P,. Cancer control in Thailand. Jpn J Clin Oncol 2002; 32 (Suppl.): S82-91.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD,. Cholangiocarcinoma. Lancet 2005; 366: 1303-14. (Pubitemid 41416587)
3. Shaib Y, El-Serag HB,. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004; 24: 115-25. (Pubitemid 38738341)
4. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM,. Biliary tract cancers. N Engl J Med 1999; 341: 1368-78.
5. Naviglio S, Caraglia M, Abbruzzese A, Chiosi E, Di Gesto D, Marra M, Romano M, Sorrentino A, Sorvillo L, Spina A, Illiano G,. Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets 2009; 13: 83-92.
6. Cho-Chung YS,. Role of cyclic AMP receptor proteins in growth, differentiation, and suppression of malignancy: new approaches to therapy. Cancer Res 1990; 50: 7093-100.
7. Miller WR, Watson DM, Jack W, Chetty U, Elton RA,. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res Treat 1993; 26: 89-94. (Pubitemid 23249120)
8. Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T,. Protein kinase A (PK-A) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 1994; 69: 738-42. (Pubitemid 24112697)
9. Cho-Chung YS, Pepe S, Clair T, Budillon A, Nesterova M,. cAMP-dependent protein kinase: role in normal and malignant growth. Crit Rev Oncol Hematol 1995; 21: 33-61. (Pubitemid 26051647)
10. Tortora G, Ciardiello F,. Protein kinase A as target for novel integrated strategies of cancer therapy. Ann N Y Acad Sci 2002; 968: 139-47. (Pubitemid 34721877)
11. Loilome W, Yongvanit P, Wongkham C, Tepsiri N, Sripa B, Sithithaworn P, Hanai S, Miwa M,. Altered gene expression in Opisthorchis viverrini-associated cholangiocarcinoma in hamster model. Mol Carcinog 2006; 45: 279-87.
12. Hsu SM, Raine L,. Protein A, avidin, and biotin in immunohistochemistry. J Histochem Cytochem 1981; 29: 1349-53. (Pubitemid 12231851)
13. Yeh CN, Jan YY, Yeh TS, Hwang TL, Chen MF,. Hepatic resection of the intraductal papillary type of peripheral cholangiocarcinoma. Ann Surg Oncol 2004; 11: 606-11.
14. Pollack A, Bae K, Khor LY, Al-Saleem T, Hammond ME, Venkatesan V, Byhardt RW, Asbell SO, Shipley WU, Sandler HM,. The importance of protein kinase A in prostate cancer: relationship to patient outcome in Radiation Therapy Oncology Group trial 92-02. Clin Cancer Res 2009; 15: 5478-84.
15. Mantovani G, Bondioni S, Lania AG, Rodolfo M, Peverelli E, Polentarutti N, Veliz Rodriguez T, Ferrero S, Bosari S, Beck-Peccoz P, Spada A,. High expression of PKA regulatory subunit 1A protein is related to proliferation of human melanoma cells. Oncogene 2008; 27: 1834-43. (Pubitemid 351430825)
16. Nesterova M, Cho-Chung YS,. A single-injection protein kinase A-directed antisense treatment to inhibit tumour growth. Nat Med 1995; 1: 528-33.
17. Cho-Chung YS, Nesterova M, Kondrashin A, Noguchi K, Srivastava R, Pepe S,. Antisense-protein kinase A: a single-gene-based therapeutic approach. Antisense Nucleic Acid Drug Dev 1997; 7: 217-23. (Pubitemid 27323083)
18. Cho-Chung YS, Nesterova M, Pepe S, Lee GR, Noguchi K, Srivastava RK, Srivastava AR, Alper O, Park YG, Lee YN,. Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front Biosci 1999; 4: D898-907.
19. Nesterova M, Cho-Chung YS,. Oligonucleotide sequence-specific inhibition of gene expression, tumor growth inhibition, and modulation of cAMP signaling by an RNA-DNA hybrid antisense targeted to protein kinase A RIalpha subunit. Antisense Nucleic Acid Drug Dev 2000; 10: 423-33. (Pubitemid 32058031)
20. Nesterova MV, Cho-Chung YS,. Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis. Clin Cancer Res 2004; 10: 4568-77. (Pubitemid 38878901)
21. Francis H, Glaser S, Ueno Y, Lesage G, Marucci L, Benedetti A, Taffetani S, Marzioni M, Alvaro D, Venter J, Reichenbach R, Fava G, et al. cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. J Hepatol 2004; 41: 528-37. (Pubitemid 39297786)
22. Roberson ED, English JD, Adams JP, Selcher JC, Kondratick C, Sweatt JD,. The mitogen-activated protein kinase cascade couples PKA and PKC to cAMP response element binding protein phosphorylation in area CA1 of hippocampus. J Neurosci 1999; 19: 4337-48. (Pubitemid 29241087)
23. Lawlor MA, Alessi DR,. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses? J Cell Sci 2001; 114: 2903-10. (Pubitemid 32821530)
24. Scheid MP, Woodgett JR,. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2001; 2: 760-8. (Pubitemid 33679838)
25. Chung JY, Hong SM, Choi BY, Cho H, Yu E, Hewitt SM,. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res 2009; 15: 660-7.
26. West KA, Brognard J, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA,. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J Clin Invest 2003; 111: 81-90. (Pubitemid 36134851)
27. Hebenstreit D, Horejs-Hoeck J, Duschl A,. JAK/STAT-dependent gene regulation by cytokines. Drug News Perspect 2005; 18: 243-9. (Pubitemid 41094927)
28. Bogorad RL, Ostroukhova TY, Orlova AN, Rubtsov PM, Smirnova OV,. Long isoform of prolactin receptor predominates in rat intrahepatic bile ducts and further increases under obstructive cholestasis. J Endocrinol 2006; 188: 345-54. (Pubitemid 43273822)
29. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA,. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr Rev 1998; 19: 225-68. (Pubitemid 29117815)
30. Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ,. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. Hepatology 2005; 42: 1329-38. (Pubitemid 43260035)
31. Taniai M, Grambihler A, Higuchi H, Werneburg N, Bronk SF, Farrugia DJ, Kaufmann SH, Gores GJ,. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004; 64: 3517-24. (Pubitemid 38657926)
32. Ashida K, Terada T, Kitamura Y, Kaibara N,. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998; 27: 974-82. (Pubitemid 28160482)
33. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Tsuneyoshi M,. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001; 14: 900-5. (Pubitemid 32889249)
34. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, Asahara T,. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 2005; 27: 973-80.
35. Settakorn J, Kaewpila N, Burns GF, Leong AS,. FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 2005; 58: 1249-54. (Pubitemid 41752767)
36. Davies SP, Reddy H, Caivano M, Cohen P,. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
37. Lochner A, Moolman JA,. The many faces of H89: a review. Cardiovasc Drug Rev 2006; 24: 261-74. (Pubitemid 46435008)